Evidence map›Paper›PMID 36582215›Full record

ArticleOphthalmology science2023

Long-Term Decrease in Intraocular Pressure in Survivors of Ebola Virus Disease in the Partnership for Research on Vaccines and Infectious Diseases in Liberia (PREVAIL) III Study.

Shwetha Mudalegundi, Robin D Ross, Jemma Larbelee, Fred Amegashie, Robert F Dolo, Grace S Prakalapakorn, Vincent Ray, Catherine Gargu, Yassah Sosu, Jennie Sackor and 10 more

Open access · goldAbstract read
In one paragraph

Article in Ophthalmology science, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 10 institutions in 3 countries.

Shwetha MudalegundiWilmer Eye Institute at Johns Hopkins, Baltimore, Maryland.
Robin D RossGlobal Retina Institute, Scottsdale, Arizona.
Jemma LarbeleeRedemption Hospital, Monrovia, Liberia.
Fred AmegashieLiberia Noncommunicable Disease Alliance, Monrovia, Liberia.
Robert F DoloNew Sight Eye Centre, Paynesville, Liberia.
Grace S PrakalapakornDepartment of Ophthalmology, Duke University, Durham, North Carolina.
Vincent RayDepartment of Ophthalmology, California Pacific Medical Center, San Francisco.
Catherine GarguPartnership for Research on Vaccines and Infectious Diseases in Liberia, Monrovia, Liberia.
Yassah SosuPartnership for Research on Vaccines and Infectious Diseases in Liberia, Monrovia, Liberia.
Jennie SackorPartnership for Research on Vaccines and Infectious Diseases in Liberia, Monrovia, Liberia.
Precious Z CooperPartnership for Research on Vaccines and Infectious Diseases in Liberia, Monrovia, Liberia.
Augustine WallacePartnership for Research on Vaccines and Infectious Diseases in Liberia, Monrovia, Liberia.
Ruth NyainPartnership for Research on Vaccines and Infectious Diseases in Liberia, Monrovia, Liberia.
Bryn BurkholderWilmer Eye Institute at Johns Hopkins, Baltimore, Maryland.
Collin Van RynDivision of Biostatistics, University of Minnesota, Minneapolis.
Bionca DavisDivision of Biostatistics, University of Minnesota, Minneapolis.
Mosoka P FallahAfrica Center for Disease, Addis Ababa, Ethiopia.
Cavan ReillyDivision of Biostatistics, University of Minnesota, Minneapolis.
Rachel J BishopNational Eye Institute, National Institutes of Health, Bethesda, Maryland.
Allen O EghrariJohns Hopkins University School of Medicine, Baltimore, MD.
Liberian Institute for Biomedical Research · LRUniversity of Minnesota · USAfrica Centres for Disease Control and Prevention · ETCalifornia Pacific Medical Center · USDuke University · USJohns Hopkins University · USNational Institutes of Health · USPlanned Parenthood Association of Liberia · LRRetina Institute · USUniversity of Liberia · LR

Funding

Wilmer Inst. Mentored Clinical Research Scholar ProgramK12EY015025 · NEI · JOHNS HOPKINS UNIVERSITY · PI James T Handa, Harry Alan Quigley · 2003 to 2026
$8.6M
CCR NIH HHS HHSN261200800001CNCI NIH HHS HHSN261200800001ENEI NIH HHS K12 EY015025NEI NIH HHS L30 EY024746
6 · The paper itself

Abstract

Objective: Survivors of Ebola virus disease (EVD) experience decreased intraocular pressure (IOP) relative to unaffected close contacts during the first year of convalescence. Whether this effect persists over time and its relationship to intraocular pathology are unclear. We sought to determine whether IOP remained lower in survivors of EVD over 4 years of follow-up and to identify associated risk factors. Design: Partnership for Research on Vaccines and Infectious Diseases in Liberia (PREVAIL) III is a 5-year, longitudinal cohort study of survivors of EVD and their close contacts and is a collaboration between the Liberian Ministry of Health and the United States National Institutes of Health. Participants: Participants who enrolled in PREVAIL III at John F. Kennedy Medical Center in Liberia, West Africa from June 2015 to March 2016 who underwent comprehensive ophthalmic evaluation annually for 5 consecutive visits. Methods: Intraocular pressure was measured at each visit by a handheld rebound tonometer using sterile tips. Comparisons are made between antibody-positive survivors and antibody-negative close contacts. Main Outcome Measures: Intraocular pressure, measured in mmHg, at each study visit. Results: Of 565 antibody-positive survivors and 644 antibody-negative close contacts enrolled in the study at baseline, the majority of participants returned annually, with 383 (67.8%) and 407 (63.2%) participants, respectively, presenting for the final study visit at a median of 60 months after symptom onset. A sustained, relative decrease in IOP was observed in survivors relative to close contacts, with mean difference of -0.72 mmHg (95% confidence interval [CI] -1.18 to -0.27) at the final study visit. This difference remained constant throughout the study period ( Conclusions: Survivors of EVD experienced a sustained decrease in IOP relative to close contacts over a 5-year period after EVD. The results highlight the importance of considering long-term sequelae of emerging infectious diseases within a population. Financial Disclosures: Proprietary or commercial disclosure may be found after the references.

Indexed as

CI, confidence intervalEbolaEbola virus diseaseEVD, Ebola virus diseaseglobal ophthalmologyintraocular pressureIOP, intraocular pressureLiberiaPREVAIL, Partnership for Research on Vaccines and Infectious Diseases in Liberia

Identifiers

PMID36582215
PMCPMC9792389
OpenAlexW4308326715

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.